Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches. Oncology remains dominant (38%), but there is increasing activity in metabolic (13%) and hematological (10%) areas.
Notably, in December 2023, the FDA approved Casgevy — the first CRISPR-based therapy — for sickle cell disease and beta-thalassemia. By Q3 2024, over half of newly initiated gene therapy trials targeted non-oncology indications.
Axcellant has extensive experience in this space, supporting clinical programs involving CAR-T cells, cancer vaccines, and stem cells. We help biotech teams manage the regulatory, logistical, and operational complexity behind these groundbreaking therapies.
Discover our capabilities in ATMP trial delivery.
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…
Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While…
Copyright @ 2025 Axcellant